Encapsulation is known to deteriorate the performance of subcutaneous (SQ) continuous glucose monitors (CGMs), preventing these devices from meeting the long-term functionality requirements for widespread use and creating a bottleneck in artificial pancreas (AP) development. 1, 2 While recent studies of implanted SQ sensors have shown promising results, there is still much room for improvement, including the reduction of encapsulation-induced sensor lag. 3, 4 We present a proof-of-concept study of a novel flushing assembly to routinely clean the sensor surface, thereby prolonging its lifetime. Placing the sensor in the intraperitoneal (IP) space allows flushing with saline that would not be possible in the restricted SQ space.
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Fluorescent glucose sensors were implanted in the SQ or IP space of sheep. Sensors were provided by the manufacturer in a lengthened, tethered format. The IP sensors were modified with silicone tubing, flush port, Dacron cuff, and adaptors to allow flushing with saline solution. Experiments were conducted under an IACUC-approved protocol by BioSurg, Inc (Davis, CA). After preliminary testing to optimize the flushing procedure, long-term responsiveness was evaluated with an IP sensor placed in 1 sheep and an SQ sensor placed in a second sheep. The IP sensor was flushed weekly with saline. Glucose response challenges were performed periodically over 3 months by infusing 0.5 g/kg dextrose through an ear vein over 60 s (13 challenges over 114 days for IP, 9 challenges over 91 days for SQ). The results are summarized in Figure 1 .
The IP sensor demonstrated anomalously slow response during the first challenge (day 8) due to tissue trauma following implantation, which is known to cause inflammatory response. 3 Excluding day 8, the IP sensor maintained consistent responsiveness throughout the 114-day period, with time to half-maximum (t 1/2 ) between 2.7 and 4.7 min and time to maximum (t max ) between 11.6 and 17.2 min. Conversely, the nonflushed sensor in the SQ space gradually lost responsiveness, with t 1/2 between 2.6 and 13.5 min and t max between 9.7 and 72 min. By 91 days following implantation, the SQ sensor signal did not peak within the 60-min testing period (see Figure 1B) .
The development of long-term implantable CGMs is a key step toward making this technology more practical; however, CGM performance is hindered by diffusion lag and loss of sensitivity caused by encapsulation driven by the foreign body response. 2, 3 The IP space has already been shown to be valuable to AP applications, with experimental evidence showing both faster insulin action and faster glucose sensing in this space. 5, 6 The performance of the flushed IP sensor presented here far exceeded that of the conventional SQ sensor after long implantation periods, showing promise for further investigation of the flushing method.
This proof-of-concept study introduces the use of a flushing mechanism to allow CGM in the IP space with consistent responsiveness during 3 months in vivo. Future iterations of this system will utilize automated flushing of the sensing element with small volumes of fluid drawn from the patient's bodily fluids. Data generated from this study will guide the development of an IP CGM to enable an implantable AP and improve practicality of CGM use for day-to-day diabetes therapy. The number of days since insertion for each challenge is indicated on the y-axis, while the time-course of the challenge is shown on the x-axis. The time at which the signal reached half-maximum is indicated by a blue star for SQ and a red plus sign for IP. The time at which the signal reached maximum is indicated by a blue square for SQ and a red circle for IP. The length of the dotted line connecting each pair of points shows the amount of time that passed between reaching half-maximum and reaching maximum.
